LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 6.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 338,024 shares of the company’s stock after selling 22,096 shares during the period. Geode Capital Management LLC owned about 1.23% of LENZ Therapeutics worth $8,027,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in LENZ. Parkman Healthcare Partners LLC acquired a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at approximately $3,308,000. The Manufacturers Life Insurance Company purchased a new position in LENZ Therapeutics in the third quarter worth $743,000. Bank of New York Mellon Corp lifted its holdings in LENZ Therapeutics by 255.4% in the second quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company’s stock valued at $687,000 after acquiring an additional 28,556 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of LENZ Therapeutics by 197.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after purchasing an additional 81,901 shares in the last quarter. Finally, State Street Corp grew its stake in shares of LENZ Therapeutics by 18.7% during the 3rd quarter. State Street Corp now owns 289,154 shares of the company’s stock worth $6,865,000 after purchasing an additional 45,600 shares during the period. Hedge funds and other institutional investors own 54.32% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Raymond James started coverage on LENZ Therapeutics in a research note on Friday, September 27th. They set an “outperform” rating and a $37.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LENZ Therapeutics presently has a consensus rating of “Buy” and an average target price of $35.40.

LENZ Therapeutics Stock Performance

NASDAQ:LENZ opened at $28.29 on Friday. LENZ Therapeutics, Inc. has a twelve month low of $14.42 and a twelve month high of $38.93. The firm has a 50-day moving average price of $32.46 and a two-hundred day moving average price of $25.80.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the previous year, the firm earned ($1.33) EPS. On average, equities analysts anticipate that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current year.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.